{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:23:06Z","timestamp":1782321786932,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pancreatic ductal adenocarcinoma has a high mortality rate, with a 5-year survival rate of ~\u200912%. Therefore, developing new targeted therapies is urgently needed. ONC-201, a promising candidate, is currently undergoing clinical trials. The main objective of the present work is to investigate the anti-tumour activity of ONC-201 and its two fluorinated analogues (TBP-134, TBP-135). The viability of two pancreatic adenocarcinoma cell lines (PANC-1, MIA PaCa-2) and three other tumour cell lines (A2058, EBC-1, COLO-205) was assessed after 72-hour treatment with drugs at 0.5, 10, and 25 \u00b5M. Significant antiproliferative effects were observed, with 0.5 \u00b5M TBP-134 achieving the highest potency, reducing cell viability to approximately 50%. None of the molecules exhibited significant cytotoxicity toward normal human dermal fibroblast cells or cardiomyocytes, indicating a selective anti-tumour profile. The analogues showed more effective results than ONC201 on PANC-1 cells (IC<jats:sub>50<\/jats:sub>: 0.35 and 1.8 \u00b5M vs. IC<jats:sub>50<\/jats:sub>: 6.1 \u00b5M, respectively). All analogues induced G2\/M phase arrest followed by apoptosis in PANC-1 cells. The site of the fluorination influenced the mechanism of apoptotic action of these compounds. Overall, TBP-134 showed superior efficacy, making it a promising candidate for structural optimization within the imipridone family to develop more effective, selective treatments for pancreatic tumours.<\/jats:p>","DOI":"10.1038\/s41598-025-00070-x","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:25:08Z","timestamp":1746620708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line"],"prefix":"10.1038","volume":"15","author":[{"given":"Zs\u00f3fia","family":"Sz\u00e1sz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9la","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton","family":"Kalabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"B\u00e1r\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Czuczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antal","family":"Cs\u00e1mpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Lajk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"K\u0151hidai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"1","key":"70_CR1","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson, A., Andersson, R. & Ansari, D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci. Rep. 10 (1), 16425 (2020).","journal-title":"Sci. Rep."},{"issue":"5","key":"70_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: Changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164 (5), 752\u2013765 (2023).","journal-title":"Gastroenterology"},{"issue":"8","key":"70_CR3","first-page":"626","volume":"89","author":"MS De La Cruz","year":"2014","unstructured":"De La Cruz, M. S., Young, A. P. & Ruffin, M. T. Diagnosis and management of pancreatic cancer. Am. Fam Physician. 89 (8), 626\u2013632 (2014).","journal-title":"Am. Fam Physician"},{"issue":"43","key":"70_CR4","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan, A. et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 24 (43), 4846\u20134861 (2018).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"70_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18632\/oncoscience.133","volume":"2","author":"YE Greer","year":"2015","unstructured":"Greer, Y. E. & Lipkowitz, S. TIC10\/ONC201: A bend in the road to clinical development. Oncoscience 2 (2), 75\u201376 (2015).","journal-title":"Oncoscience"},{"issue":"15","key":"70_CR6","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","volume":"23","author":"MN Stein","year":"2017","unstructured":"Stein, M. N. et al. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin. Cancer Res. 23 (15), 4163\u20134169 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"70_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-21-4030","volume":"28","author":"PM Anderson","year":"2022","unstructured":"Anderson, P. M. et al. Phase II study of ONC201 in neuroendocrine tumors including pheochromocytoma-paraganglioma and desmoplastic small round cell tumor. Clin. Cancer Res. 28 (9), 1773\u20131782 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"171","key":"70_CR8","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","volume":"5","author":"JE Allen","year":"2013","unstructured":"Allen, J. E. et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl Med. 5 (171), 171ra17 (2013).","journal-title":"Sci. Transl Med."},{"issue":"4","key":"70_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bbrc.2016.05.106","volume":"476","author":"Q Zhang","year":"2016","unstructured":"Zhang, Q., Wang, H., Ran, L., Zhang, Z. & Jiang, R. The preclinical evaluation of TIC10\/ONC201 as an anti-pancreatic cancer agent. Biochem. Biophys. Res. Commun. 476 (4), 260\u2013266 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"70_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ccell.2019.04.010","volume":"35","author":"S Wang","year":"2019","unstructured":"Wang, S. & Dougan, D. A. The direct molecular target for Imipridone ONC201 is finally established. Cancer Cell. 35 (5), 707\u2013708 (2019).","journal-title":"Cancer Cell."},{"issue":"11","key":"70_CR11","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1021\/acschembio.9b00347","volume":"14","author":"KS Wong","year":"2019","unstructured":"Wong, K. S. & Houry, W. A. Chemical modulation of human mitochondrial ClpP: Potential application in cancer therapeutics. ACS Chem. Biol. 14 (11), 2349\u20132360 (2019).","journal-title":"ACS Chem. Biol."},{"issue":"Suppl 7","key":"70_CR12","doi-asserted-by":"publisher","first-page":"S1239","DOI":"10.21037\/tcr.2017.10.03","volume":"6","author":"MD Ralff","year":"2017","unstructured":"Ralff, M. D., Lulla, A. R., Wagner, J. & El-Deiry, W. S. ONC201: A new treatment option being tested clinically for recurrent glioblastoma. Transl Cancer Res. 6 (Suppl 7), S1239\u2013s1243 (2017).","journal-title":"Transl Cancer Res."},{"issue":"1","key":"70_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/157488709787047530","volume":"4","author":"CA Bellail","year":"2009","unstructured":"Bellail, C. A., Qi, L., Mulligan, P., Chhabra, V. & Hao, C. TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. Rev. Recen. Clin. Trial. 4 (1), 34\u201341 (2009).","journal-title":"Rev. Recen. Clin. Trial"},{"issue":"7\u20138","key":"70_CR14","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","volume":"39","author":"C Falschlehner","year":"2007","unstructured":"Falschlehner, C., Emmerich, C. H., Gerlach, B. & Walczak, H. TRAIL signalling: Decisions between life and death. Int. J. Biochem. Cell. Biol. 39 (7\u20138), 1462\u20131475 (2007).","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"6","key":"70_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","volume":"17","author":"S von Karstedt","year":"2017","unstructured":"von Karstedt, S., Montinaro, A. & Walczak, H. Exploring the trails less travelled: TRAIL in cancer biology and therapy. Nat. Rev. Cancer. 17 (6), 352\u2013366 (2017).","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"70_CR16","doi-asserted-by":"publisher","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","volume":"58","author":"EP Gillis","year":"2015","unstructured":"Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J. & Meanwell, N. A. Applications of fluorine in medicinal chemistry. J. Med. Chem. 58 (21), 8315\u20138359 (2015).","journal-title":"J. Med. Chem."},{"issue":"4","key":"70_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1021\/jm3012068","volume":"56","author":"R Wilcken","year":"2013","unstructured":"Wilcken, R., Zimmermann, M. O., Lange, A., Joerger, A. C. & Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 56 (4), 1363\u20131388 (2013).","journal-title":"J. Med. Chem."},{"issue":"1","key":"70_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","volume":"14","author":"JE Allen","year":"2015","unstructured":"Allen, J. E. et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol. Cancer. 14 (1), 99 (2015).","journal-title":"Mol. Cancer"},{"issue":"8","key":"70_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann, J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17 (8), 474\u2013502 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"70_CR20","doi-asserted-by":"publisher","first-page":"116293","DOI":"10.1016\/j.biopha.2024.116293","volume":"173","author":"Z Sz\u00e1sz","year":"2024","unstructured":"Sz\u00e1sz, Z. et al. Characterisation of the cell and molecular biological effect of peptide-based Daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line. Biomed. Pharmacother. 173, 116293 (2024).","journal-title":"Biomed. Pharmacother"},{"key":"70_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","volume":"979","author":"FK Chan","year":"2013","unstructured":"Chan, F. K., Moriwaki, K. & De Rosa, M. J. Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol. Biol. 979, 65\u201370 (2013).","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"70_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/path.3022","volume":"226","author":"GH Williams","year":"2012","unstructured":"Williams, G. H. & Stoeber, K. The cell cycle and cancer. J. Pathol. 226 (2), 352\u2013364. (2012).","journal-title":"J. Pathol."},{"issue":"4","key":"70_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.20892\/j.issn.2095-3941.2018.0030","volume":"15","author":"AM Castro-Gamero","year":"2018","unstructured":"Castro-Gamero, A. M., Pezuk, J. A., Brassesco, M. S. & Tone, L. G. G2\/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: The old, the new, and the future. Cancer Biol. Med. 15 (4), 354\u2013374 (2018).","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"70_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000187135","volume":"9","author":"RD Carvajal","year":"2009","unstructured":"Carvajal, R. D. et al. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 9 (4), 404\u2013409 (2009).","journal-title":"Pancreatology"},{"issue":"1","key":"70_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s004410000193","volume":"301","author":"G H\u00e4cker","year":"2000","unstructured":"H\u00e4cker, G. The morphology of apoptosis. Cell. Tissue Res. 301 (1), 5\u201317 (2000).","journal-title":"Cell. Tissue Res."},{"issue":"3","key":"70_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0008-6363(99)00384-3","volume":"45","author":"A Saraste","year":"2000","unstructured":"Saraste, A. & Pulkki, K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 45 (3), 528\u2013537 (2000).","journal-title":"Cardiovasc. Res."},{"key":"70_CR27","doi-asserted-by":"publisher","first-page":"628332","DOI":"10.3389\/fmolb.2021.628332","volume":"8","author":"M Snajdauf","year":"2021","unstructured":"Snajdauf, M. et al. The TRAIL in the treatment of human cancer: An update on clinical trials. Front. Mol. Biosci. 8, 628332 (2021).","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"70_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cancers10030077","volume":"10","author":"AL Kretz","year":"2018","unstructured":"Kretz, A. L. et al. Should we keep walking along the trail for pancreatic Cancer treatment?? Revisiting TNF-related apoptosis-inducing ligand for anticancer therapy. Cancers (Basel), 10(3), 77 (2018).","journal-title":"Cancers (Basel)"},{"issue":"4","key":"70_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clcc.2013.06.002","volume":"12","author":"ZA Wainberg","year":"2013","unstructured":"Wainberg, Z. A. et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin. Colorectal Cancer. 12 (4), 248\u2013254 (2013).","journal-title":"Clin. Colorectal Cancer"},{"issue":"2","key":"70_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","volume":"30","author":"A Montinaro","year":"2023","unstructured":"Montinaro, A. & Walczak, H. Harnessing TRAIL-induced cell death for cancer therapy: A long walk with thrilling discoveries. Cell. Death Differ. 30 (2), 237\u2013249 (2023).","journal-title":"Cell. Death Differ."},{"issue":"2","key":"70_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00280-010-1463-1","volume":"67","author":"RP Sahu","year":"2011","unstructured":"Sahu, R. P., Batra, S., Kandala, P. K., Brown, T. L. & Srivastava, S. K. The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother. Pharmacol. 67 (2), 481\u2013487 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"30","key":"70_CR32","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1038\/sj.onc.1204558","volume":"20","author":"H Wajant","year":"2001","unstructured":"Wajant, H. et al. Differential activation of TRAIL-R1 and \u2013\u20092 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20 (30), 4101\u20134106 (2001).","journal-title":"Oncogene"},{"issue":"4","key":"70_CR33","first-page":"444","volume":"11","author":"J Naval","year":"2019","unstructured":"Naval, J., de Miguel, D., Gallego-Lleyda, A., Anel, A. & Martinez-Lostao, L. Importance of TRAIL molecular anatomy in receptor oligomerization and signaling. Implications Cancer Therapy. 11 (4), 444 (2019).","journal-title":"Implications Cancer Therapy"},{"issue":"7","key":"70_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00109-010-0619-0","volume":"88","author":"J Lemke","year":"2010","unstructured":"Lemke, J. et al. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J. Mol. Med. (Berl). 88 (7), 729\u2013740 (2010).","journal-title":"J. Mol. Med. (Berl)"},{"issue":"8","key":"70_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/ph14080820","volume":"14","author":"A Tak\u00e1cs","year":"2021","unstructured":"Tak\u00e1cs, A. et al. The synergistic activity of bortezomib and TIC10 against A2058 melanoma cells. Pharmaceuticals (Basel), 14(8), 820 (2021).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6824","key":"70_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/35065125","volume":"410","author":"SM Srinivasula","year":"2001","unstructured":"Srinivasula, S. M. et al. A conserved XIAP-interaction motif in caspase-9 and Smac\/DIABLO regulates caspase activity and apoptosis. Nature 410 (6824), 112\u2013116 (2001).","journal-title":"Nature"},{"issue":"5","key":"70_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","volume":"35","author":"J Ishizawa","year":"2019","unstructured":"Ishizawa, J. et al. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell. 35 (5), 721\u2013737e9 (2019).","journal-title":"Cancer Cell."},{"issue":"20","key":"70_CR38","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1021\/jo000495a","volume":"65","author":"W Adam","year":"2000","unstructured":"Adam, W. & Trofimov, A. V. The effect of meta versus para substitution on the efficiency of chemiexcitation in the chemically triggered electron-transfer-initiated decomposition of spiroadamantyl dioxetanes. J. Org. Chem. 65 (20), 6474\u20136478 (2000).","journal-title":"J. Org. Chem."},{"issue":"3","key":"70_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/molecules28030978","volume":"28","author":"AM Alsibaee","year":"2023","unstructured":"Alsibaee, A. M., Al-Yousef, H. M. & Al-Salem, H. S. Quinazolinones, the winning horse in drug discovery. Molecules, 28(3), 978 (2023).","journal-title":"Molecules"},{"issue":"5","key":"70_CR40","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/molecules27051643","volume":"27","author":"D Benedetto Tiz","year":"2022","unstructured":"Benedetto Tiz, D. et al. New Halogen-Containing drugs approved by FDA in 2021: An overview on their syntheses and pharmaceutical use. Molecules, 27(5), 1643 (2022).","journal-title":"Molecules"},{"key":"70_CR41","first-page":"1500","volume-title":"Drugs Eicosanoids: Second Messengers","author":"JF Wilson","year":"1995","unstructured":"Wilson, J. F. Corticosteroids. In Drugs Eicosanoids: Second Messengers 1500\u20131501 (Springer, 1995). J.F. Wilson, Editor."},{"issue":"3","key":"70_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1021\/jm00153a015","volume":"29","author":"JM Domagala","year":"1986","unstructured":"Domagala, J. M. et al. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J. Med. Chem. 29 (3), 394\u2013404 (1986).","journal-title":"J. Med. Chem."},{"issue":"15","key":"70_CR43","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-06-0113","volume":"12","author":"B Rubio-Viqueira","year":"2006","unstructured":"Rubio-Viqueira, B. et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12 (15), 4652\u20134661 (2006).","journal-title":"Clin. Cancer Res."},{"key":"70_CR44","unstructured":"Cs\u00e1mpai, A., et al. Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity. WO2022029459A1, 10 February 2022. Available online: https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2022029459."},{"key":"70_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-61779-108-6_6","volume":"740","author":"N Ke","year":"2011","unstructured":"Ke, N., Wang, X., Xu, X. & Abassi, Y. A. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol. Biol. 740, 33\u201343 (2011).","journal-title":"Methods Mol. Biol."},{"issue":"9","key":"70_CR46","doi-asserted-by":"publisher","first-page":"12347","DOI":"10.3390\/s120912347","volume":"12","author":"SN Rampersad","year":"2012","unstructured":"Rampersad, S. N. Multiple applications of Alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sens. (Basel). 12 (9), 12347\u201312360 (2012).","journal-title":"Sens. (Basel)"},{"issue":"10","key":"70_CR47","doi-asserted-by":"publisher","first-page":"pdb-rot087247","DOI":"10.1101\/pdb.prot087247","volume":"2016","author":"LC Crowley","year":"2016","unstructured":"Crowley, L. C., Chojnowski, G. & Waterhouse, N. J. Measuring the DNA content of cells in apoptosis and at different cell-cycle stages by propidium iodide staining and flow cytometry. Cold Spring Harb Protoc. 2016 (10), pdb-rot087247 (2016).","journal-title":"Cold Spring Harb Protoc."},{"key":"70_CR48","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3762\/bjoc.14.226","volume":"14","author":"E Lajk\u00f3","year":"2018","unstructured":"Lajk\u00f3, E. et al. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids. Beilstein J. Org. Chem. 14, 2495\u20132509 (2018).","journal-title":"Beilstein J. Org. Chem."},{"issue":"1","key":"70_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184 (1), 39\u201351 (1995).","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"70_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ab.2012.07.005","volume":"429","author":"NC Zembruski","year":"2012","unstructured":"Zembruski, N. C., Stache, V., Haefeli, W. E. & Weiss, J. 7-Aminoactinomycin D for apoptosis staining in flow cytometry. Anal. Biochem. 429 (1), 79\u201381 (2012).","journal-title":"Anal. Biochem."},{"key":"70_CR51","doi-asserted-by":"crossref","unstructured":"Sebesta, M. et al. HoloMonitor M4: Holographic imaging cytometer for real-time kinetic label-free live-cell analysis of adherent cells. SPIE BiOS. Vol. 9718. (SPIE, 2016).","DOI":"10.1117\/12.2216731"},{"key":"70_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4939-7357-6_4","volume":"1683","author":"BS Mandavilli","year":"2018","unstructured":"Mandavilli, B. S., Yan, M. & Clarke, S. Cell-Based high content analysis of cell proliferation and apoptosis. Methods Mol. Biol. 1683, 47\u201357 (2018).","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"70_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/ph15030314","volume":"15","author":"M Kalabay","year":"2022","unstructured":"Kalabay, M. et al. Investigation of the antitumor effects of tamoxifen and its ferrocene-linked derivatives on pancreatic and breast cancer cell lines. Pharmaceuticals (Basel), 15(3), 314 (2022).","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00070-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:03:26Z","timestamp":1746623006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00070-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human and animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"15925"}}